Ingredient or product comparison
Topical vs Subcutaneous Administration: What the 2025 Trials Show
The Stanford TB-4 trial used subcutaneous injection at 500 mcg twice weekly, administered 2–3 mm lateral to the hairline to target dermal papilla cells directly. Injectable administration achieves higher local bioavailability because peptides bypass the stratu
This source-based comparison does not add ratings or recommend a winner.
- The Stanford TB-4 trial used subcutaneous injection at 500 mcg twice weekly, administered 2–3 mm lateral to the hairline to target dermal papilla cells directly. Injectable administration achieves higher local bioavailability because peptides bypass the stratum corneum. The outermost skin layer that blocks molecular penetration above 500 Daltons. TB-4 has a molecular weight of 4,963 Daltons, meaning topical application without penetration enhancers achieves less than 5% dermal delivery.
- Copper peptide GHK-Cu, at 340 Daltons, penetrates the stratum corneum more effectively, which is why the Dermatologic Surgery trial used topical application (2% serum, once daily) and still achieved 12–18% density improvement at 24 weeks. Injectable GHK-Cu wasn't tested in that trial, but intradermal administration would likely show faster onset. One small pilot study at University of Naples in 2024 found 9% density improvement at 12 weeks with monthly intradermal GHK-Cu injections vs 14 weeks for daily topical use.
- Here's the honest answer: topical peptides work if the molecular weight is below 500 Daltons and the formulation includes penetration enhancers like dimethyl sulfoxide (DMSO) or liposomal encapsulation. For larger peptides like TB-4, topical application is essentially ineffective. You're applying an expensive compound that sits on the stratum corneum and degrades without reaching dermal papilla cells. Injectable administration requires more precision and carries minor injection site risks (temporary erythema, rare infection if sterile technique isn't followed), but bioavailability is 15–20× higher than topical for peptides above 1,000 Daltons.
- Most consumer formulations don't disclose molecular weight or penetration-enhancing ingredients, which is why replication of published trial results is inconsistent. If a product claims TB-4 efficacy from topical application without listing DMSO, liposomes, or microneedling as part of the protocol, the peptide isn't reaching dermal layers in meaningful concentrations.